GLP-1 RAs significantly reduced MACE in high-cardiovascular-risk T2D patients, confirming cardioprotective benefits in a large real-world or meta-analytic evaluation.
CV protection confirmedGLP-1 drugs reduce heart attacks, strokes, and cardiovascular death in diabetic patients at high risk
What the researchers found
GLP-1 RAs significantly reduced MACE in T2D patients with high cardiovascular risk.
Why it matters
Cardiovascular disease is the leading cause of death in T2D. Confirming GLP-1 cardioprotection in real-world settings strengthens prescribing confidence.
How the study worked
Analysis evaluating GLP-1 RA impact on MACE in high-CV-risk T2D patients.
What this study cannot tell us
Details depend on full paper methodology.
How to read the evidence
Confirmatory analysis of established benefit.
When this study was published
Published in 2025.
The bigger picture
GLP-1 drugs are now established cardiovascular medicines, not just diabetes drugs.
Questions still open
- Should all high-CV-risk T2D patients receive GLP-1 drugs?
- Which GLP-1 drug provides the strongest cardioprotection?
- Does benefit extend to low-CV-risk T2D?
Common questions
Do GLP-1 drugs protect the heart?
Should all diabetic patients take GLP-1 drugs?
Read the original research
Association Between Glucagon-Like Peptide-1 Receptor Agonists and Major Adverse Cardiovascular Outcomes Based on Race and Sex Among Patients With and Without Diabetes Mellitus: A Meta-Analysis of Nine Randomized Controlled Trials.
Reviews in cardiovascular medicine, 27(1), 45797
Citation
Jaiswal, Vikash; Mashkoor, Yusra; Borra, Vamsikalyan; Gera, Asmita; Patel, Nirmit; Jitta, Sahas Reddy; Nasir, Yusra Minahil; Sharma, Prachi; Mattumpuram, Jishanth. (2026). Association Between Glucagon-Like Peptide-1 Receptor Agonists and Major Adverse Cardiovascular Outcomes Based on Race and Sex Among Patients With and Without Diabetes Mellitus: A Meta-Analysis of Nine Randomized Controlled Trials.. Reviews in cardiovascular medicine, 27(1), 45797. https://doi.org/10.31083/RCM45797